Clinical Trial Update: Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults [Phase 2]

View source ↗

Summary

This ClinicalTrials.gov update reports a Phase 2 study evaluating zoledronic acid or denosumab to prevent bone loss in critically ill adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• Denosumab (denosumab)
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Australian and New Zealand Intensive Care Research Centre | Conditions: Critical Illness, Osteoporosis | Phase 2 | Status: RECRUITING